Sunifiram

Sunifiram at a Glance

Sunifiram, also written DM-235, is a small synthetic molecule developed by an Italian academic medicinal-chemistry group as a cognition-enhancer. It is a piperazine — a simplified structural relative of the older nootropic piracetam — and it draws attention because it is extraordinarily potent in animal memory tests, active in rodents at microgram-per-kilogram doses roughly a thousand times lower than piracetam’s.

It is not something you eat or make in your body. There is no natural source: sunifiram is produced entirely by chemical synthesis, and it was never developed into an approved medicine. Because the original chemists chose not to patent it, it drifted out of the lab and now circulates online as an unregulated research chemical.

There is no sunifiram deficiency to correct. Every reported effect is an extra imposed on a normal — or experimentally damaged — nervous system, and the strongest findings are the rescue of drug- or lesion-induced memory deficits in rodents, not enhancement of a healthy brain. The animal data are genuinely interesting and mechanistically coherent, but the entire evidence base is preclinical: no human trials, no human dosing, no human safety data. Sunifiram is best understood as an unstudied compound in people, not a proven cognitive enhancer.

What It’s Used For

Sunifiram has no approved medical use. The list below reflects what has actually been studied — all of it in rodents and cell preparations.

• Memory protection in amnesia models — reverses drug-induced amnesia in mice and rats across several chemical models. The most replicated finding, but animal-only, and about rescuing a deficit rather than boosting normal memory.
• Cognition in a neurodegeneration model — restored memory and synaptic plasticity in a single rodent model of Alzheimer’s-like damage. Mechanistically detailed, but from one lab and one study.

Be sceptical of the online framing of sunifiram as a proven smart drug for healthy people. There is not a single human study of memory, focus, learning or mood, so any claim about what it does in a person is extrapolation from mice. Claims of specific human doses, safe use, or long-term benefit have no evidence behind them at all.

How It Works

Sunifiram works on the brain’s main excitatory glutamate signalling system, and it does so indirectly — in standard binding assays it shows no measurable affinity for the major brain receptors or ion channels, so it is not a simple key-in-a-lock drug. The current model, built mostly from mouse hippocampal slice work, is that sunifiram stimulates the glycine co-agonist site of the NMDA receptor, one of the switches that gates long-term potentiation — the strengthening of synapses that underlies learning ^{5Reference 5Moriguchi S et al. · 2013Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via the glycine-binding site of the NMDA receptor — electrophysiologyView study →}. This sets off an internal cascade, activating the enzymes CaMKII and PKCα and the Src-family kinases, which in turn phosphorylate and potentiate AMPA receptors, the workhorses of fast excitatory transmission ^{5,6Reference 5Moriguchi S et al. · 2013Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via the glycine-binding site of the NMDA receptor — electrophysiologyView study →Reference 6Moriguchi S et al. · 2013AnimalNovel nootropic drug sunifiram improves cognitive deficits via CaM kinase II and protein kinase C activation in olfactory bulbectomized mice — animal studyView study →}. The net effect in tissue is stronger, more durable synaptic responses. Sunifiram also increases release of acetylcholine, central to attention and memory, from rat cerebral cortex ^{2,4Reference 2Galeotti N et al. · 2003In vitroAMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram) — mouse and in vitroView study →Reference 4Romanelli MN et al. · 2006ReviewPharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers — reviewView study →}. Because it enhances AMPA-mediated transmission, it has been described as ampakine-like.

One wrinkle explains why results can look inconsistent, and why more is not better: in slice experiments sunifiram’s effect on long-term potentiation follows a bell-shaped dose-response, peaking around 10 nM and falling off at higher concentrations ^{5Reference 5Moriguchi S et al. · 2013Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via the glycine-binding site of the NMDA receptor — electrophysiologyView study →}. Effects that depend on hitting a narrow concentration window are notoriously hard to reproduce and translate.

The framing that matters most is that this is enhancement, not repletion. There is no bodily requirement for sunifiram and no deficiency it fixes. In the animal studies the clearest effects are the reversal of induced impairments — amnesia caused by scopolamine and other drugs, or memory loss from a brain lesion — rather than improvement in intact, healthy animals ^{1,6Reference 1Ghelardini C et al. · 2002AnimalDM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer — mouse and ratView study →Reference 6Moriguchi S et al. · 2013AnimalNovel nootropic drug sunifiram improves cognitive deficits via CaM kinase II and protein kinase C activation in olfactory bulbectomized mice — animal studyView study →}.

Pharmacology & Research

Sunifiram (DM-235) is a synthetic piperazine cognition-enhancer, functionally described as ampakine-like, first characterised in the early 2000s. The evidence posture is unusual: the compound is pharmacologically well-studied but clinically unstudied — a coherent, multi-paper preclinical mechanism exists, yet there are no human trials of any kind. Because sunifiram corrects no deficiency, every effect is an addition to normal physiology, and the strongest signals come from rescuing induced deficits in rodents rather than enhancing healthy cognition. There is no human pharmacokinetic or bioavailability data, so nothing here can be translated into a dose, an effect size, or a safety margin for people.

Evidence by IndicationStrength of support · Beta

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. Because every sunifiram application is preclinical, all scores sit in the lowest band by design. Each application links down to its write-up.

01Memory protection in amnesia modelsShaky24%Multiple rodent amnesia models, two labs, oral and injected; animal-only, deficit-rescue, no human data

02Cognition in a neurodegeneration modelShaky13%Single rodent lesion study, one lab, mechanistically detailed but unreplicated

Mechanisms

Pharmacokinetics

There is no human pharmacokinetic data for sunifiram: absorption, bioavailability, metabolism, half-life and food effects are all unknown in people. In rodents it is active both orally and by injection at very low doses, roughly 0.001–1 mg/kg, and its potency is estimated at about four orders of magnitude greater than piracetam ^{1,4Reference 1Ghelardini C et al. · 2002AnimalDM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer — mouse and ratView study →Reference 4Romanelli MN et al. · 2006ReviewPharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers — reviewView study →}. The most decision-relevant observation is the bell-shaped dose-response seen in hippocampal slices — the effect peaks around 10 nM and diminishes at higher concentrations ^{5Reference 5Moriguchi S et al. · 2013Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via the glycine-binding site of the NMDA receptor — electrophysiologyView study →} — implying a narrow effective window rather than a more-is-better relationship. No half-life or clearance value can be quoted for humans.

Clinical trials

There is no registered human trial activity for sunifiram. A ClinicalTrials.gov search for “sunifiram” and “DM-235” returns zero studies, and no human clinical publications exist in PubMed. Because the compound is unpatented there has been essentially no industry incentive to fund clinical development — the original chemists have publicly noted that it reached consumer websites instead of the clinic ^{8Reference 8Gualtieri F · 2016Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings — commentaryView study →}.

Last checked: August 2026.

Dietary Sources

Sunifiram has no dietary source. It does not occur in food, plants or the human body — it is a purely synthetic molecule, created by molecular simplification of a bicyclic nootropic scaffold into a smaller piperazine, and produced only by chemical synthesis in a laboratory ^{3Reference 3Manetti D et al. · 2000Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity — medicinal chemistryView study →}. There is therefore no dietary route to it, and no natural-versus-supplement comparison to make.

Dosage

There is no established human dose for sunifiram, and none can be recommended. The figures circulated on vendor and forum sites are extrapolated from animal studies and anecdote, not derived from any human pharmacokinetic or dose-finding work.

For context only, the doses studied in research were in rodents: roughly 0.001–0.1 mg/kg by injection and 0.01–1.0 mg/kg orally in mice, with the compound reported to be about 1,000-fold more potent than piracetam in those models ^{1,4,6Reference 1Ghelardini C et al. · 2002AnimalDM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer — mouse and ratView study →Reference 4Romanelli MN et al. · 2006ReviewPharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers — reviewView study →Reference 6Moriguchi S et al. · 2013AnimalNovel nootropic drug sunifiram improves cognitive deficits via CaM kinase II and protein kinase C activation in olfactory bulbectomized mice — animal studyView study →}. Animal effects also followed an inverted-U dose-response, so scaling up is not expected to scale benefit ^{5Reference 5Moriguchi S et al. · 2013Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via the glycine-binding site of the NMDA receptor — electrophysiologyView study →}. Interspecies dose conversion for an unstudied compound is not valid. Because sunifiram is sold as an unregulated research chemical, the actual content and purity of any given product is unknown, which compounds the impossibility of a meaningful dose.

Safety

Sunifiram’s safety profile in humans is unstudied, not clean. Absence of reported harms reflects absence of research, not evidence of safety.

Safety at a Glance

Research compound

• Not an approved drug or supplement. Sunifiram circulates only as an unregulated research chemical, so manufacturing quality, purity and dose accuracy are not guaranteed.
• No human safety data of any kind. Toxicity, organ effects, drug interactions and long-term consequences are entirely uncharacterised.
• Effect follows an inverted-U in animals. Higher doses do not mean stronger effects; the active window in rodent studies is narrow, so self-experimentation has no rational dosing basis.
• Pregnancy and lactation not assessed. No reproductive or developmental data exist in any species.
• No motor or sedative impairment at effective doses in rodents. Rota-rod and hole-board testing showed no coordination or spontaneous-activity deficits — an animal-only finding, not a human safety claim.

Full Safety & Interactions Detail

Adverse effects in humans are unknown because no human study or systematic surveillance exists. In rodents, effective anti-amnesic doses did not impair motor coordination or spontaneous activity, and did not modify the induction of anaesthesia beyond shortening pentobarbitone hypnosis ^{1Reference 1Ghelardini C et al. · 2002AnimalDM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer — mouse and ratView study →} — but these are narrow behavioural readouts in animals, and say nothing about human organ toxicity, cardiovascular effects or chronic exposure.

Because sunifiram acts on glutamatergic signalling, there is a mechanistic — though entirely untested — concern about excitatory over-activation, and about interaction with drugs or conditions that lower seizure threshold or modulate glutamate. None of this has been studied, and drug-interaction data do not exist for any class.

Two structural cautions are worth stating plainly. First, in structure-activity work on this chemical series, small modifications produced analogues with the opposite, amnesia-inducing activity — underscoring that “sunifiram-like” research chemicals are not interchangeable, and that mislabelled or impure product carries real, unpredictable risk ^{7Reference 7Scapecchi S et al. · 2004Structure-activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition-enhancing drugsView study →}.

Second, the compound’s own developers have publicly described its migration from the lab to the web as a failure of oversight, precisely because long-term toxicity was never characterised ^{8Reference 8Gualtieri F · 2016Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings — commentaryView study →}.

Independent of sunifiram specifically, reviews of cognitive enhancers in healthy people conclude that benefits are uncertain and temporary, while stimulant-type mechanisms can carry cardiovascular, neurological and dependence risks ^{9Reference 9Napoletano F et al. · 2022ReviewBenefits and harms of ‘smart drugs’ (nootropics) in healthy individuals — reviewView study →}.

Scope disclosure. Interactions assessed? No — no human interaction data for any drug class; only a mechanistic glutamatergic concern. Pregnancy/lactation assessed? No — no data in any species. Upper limit established? No — no human toxicology, no NOAEL, no established safe dose.

Pregnancy & Lactation

⚠ Avoid in pregnancy⚠ Avoid while breastfeeding

Not established. There are no reproductive, developmental or lactation data for sunifiram in humans or animals, and no way to assess its transfer into milk or its effects on a fetus or nursing infant. Given the complete absence of safety data and its status as an unregulated research chemical, sunifiram should not be used during pregnancy or breastfeeding.

References

1. Ghelardini C, Galeotti N, Gualtieri F, et al. (2002). DM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer — mouse and rat. Naunyn-Schmiedeberg’s Archives of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/12070754/
2. Galeotti N, Ghelardini C, Pittaluga A, et al. (2003). AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram) — mouse and in vitro. Naunyn-Schmiedeberg’s Archives of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/14600801/
3. Manetti D, Ghelardini C, Bartolini A, et al. (2000). Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity — medicinal chemistry. Journal of Medicinal Chemistry. https://pubmed.ncbi.nlm.nih.gov/11087574/
4. Romanelli MN, Galeotti N, Ghelardini C, et al. (2006). Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers — review. CNS Drug Reviews. https://pubmed.ncbi.nlm.nih.gov/16834757/
5. Moriguchi S, Tanaka T, Narahashi T, et al. (2013). Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via the glycine-binding site of the NMDA receptor — electrophysiology. Hippocampus. https://pubmed.ncbi.nlm.nih.gov/23733502/
6. Moriguchi S, Tanaka T, Narahashi T, Fukunaga K (2013). Novel nootropic drug sunifiram improves cognitive deficits via CaM kinase II and protein kinase C activation in olfactory bulbectomized mice — animal study. Behavioural Brain Research. https://pubmed.ncbi.nlm.nih.gov/23295391/
7. Scapecchi S, Martini E, Manetti D, et al. (2004). Structure-activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition-enhancing drugs. Bioorganic & Medicinal Chemistry. https://pubmed.ncbi.nlm.nih.gov/14697772/
8. Gualtieri F (2016). Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings — commentary. Journal of Enzyme Inhibition and Medicinal Chemistry. https://pubmed.ncbi.nlm.nih.gov/25831025/
9. Napoletano F, Schifano F, Corkery JM, et al. (2022). Benefits and harms of ‘smart drugs’ (nootropics) in healthy individuals — review. Drugs. https://pubmed.ncbi.nlm.nih.gov/35366192/

View all 9 references▾